×
AleAnna Net Cash Flow 2022-2025 | ANNA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
AleAnna net cash flow from 2022 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
AleAnna Net Cash Flow 2022-2025 | ANNA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
AleAnna net cash flow from 2022 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$80.2B
Zoetis (ZTS)
$68.3B
Daiichi Sankyo, - (DSNKY)
$47.1B
Takeda Pharmaceutical (TAK)
$46.9B
BeOne Medicines - (ONC)
$32.3B
Sandoz Group AG (SDZNY)
$26.4B
Summit Therapeutics (SMMT)
$20.8B
Merck (MKKGY)
$17.3B
Shionogi (SGIOY)
$14.5B
United Therapeutics (UTHR)
$13.8B
Neurocrine Biosciences (NBIX)
$13.2B
Orion OYJ (ORINY)
$11.7B
IPSEN (IPSEY)
$10.9B
Stevanato Group S.p.A (STVN)
$7.7B
Corcept Therapeutics (CORT)
$7.3B
Madrigal Pharmaceuticals (MDGL)
$6.8B
Grifols, S.A (GRFS)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.9B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.4B
Hypermarcas (HYPMY)
$3.1B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Procaps Group, S.A (PROCF)
$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.1B
Ocular Therapeutix (OCUL)
$1.9B
BioCryst Pharmaceuticals (BCRX)
$1.8B